ADC Therapeutics SA Revenue From Contracts With Customers
ADC Therapeutics SA (ADCT) reported Revenue From Contracts With Customers of $14.49 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueFromContractsWithCustomers · last filed 2023-11-07
- ADC Therapeutics SA revenue from contracts with customers for the quarter ending 2023-09-30 was $14.49M, a 81.01% decline year-over-year.
- ADC Therapeutics SA revenue from contracts with customers for the quarter ending 2023-06-30 was $19.28M, a 11.52% increase year-over-year.
- ADC Therapeutics SA revenue from contracts with customers for the quarter ending 2023-03-31 was $18.99M, a 59.16% decline year-over-year.
- ADC Therapeutics SA revenue from contracts with customers for the quarter ending 2022-12-31 was $69.80M, a 310.34% increase year-over-year.
| Period end | Revenue From Contracts With Customers 3 month | Revenue From Contracts With Customers 6 month | Revenue From Contracts With Customers 9 month | Revenue From Contracts With Customers 12 month |
|---|---|---|---|---|
| 2023-09-30 | $14.49M 6-K · filed 2023-11-07 | $33.78M derived: sum of 2 quarters · filed 2023-11-07 | $52.77M 6-K · filed 2023-11-07 | $122.57M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $19.28M 6-K · filed 2023-08-08 | $38.27M 6-K · filed 2023-08-08 | $108.07M derived: sum of 3 quarters · filed 2023-08-08 | $184.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $18.99M 6-K · filed 2023-05-09 | $88.79M derived: sum of 2 quarters · filed 2023-05-09 | $165.11M derived: sum of 3 quarters · filed 2023-11-07 | $182.40M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $69.80M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $146.12M derived: sum of 2 quarters · filed 2023-11-07 | $163.41M derived: sum of 3 quarters · filed 2023-11-07 | $209.91M 20-F · filed 2023-03-15 |
| 2022-09-30 | $76.32M 6-K · filed 2023-11-07 | $93.61M derived: sum of 2 quarters · filed 2023-11-07 | $140.11M 6-K · filed 2023-11-07 | $157.12M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $17.29M 6-K · filed 2023-08-08 | $63.79M 6-K · filed 2023-08-08 | $80.80M derived: sum of 3 quarters · filed 2023-08-08 | $93.95M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $46.50M 6-K · filed 2023-05-09 | $63.51M derived: sum of 2 quarters · filed 2023-05-09 | $76.66M derived: sum of 3 quarters · filed 2023-05-09 | $80.42M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $17.01M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $30.16M derived: sum of 2 quarters · filed 2023-03-15 | $33.92M derived: sum of 3 quarters · filed 2023-03-15 | $33.92M 20-F · filed 2023-03-15 |
| 2021-09-30 | $13.15M 6-K · filed 2022-11-08 | $16.91M derived: sum of 2 quarters · filed 2022-11-08 | $16.91M 6-K · filed 2022-11-08 | |
| 2021-06-30 | $3.76M 6-K · filed 2022-08-09 | $3.76M 6-K · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 6-K · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 20-F · filed 2023-03-15 | |||
| 2019-12-31 | $2.34M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $1.14M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |